Advancing HIV/AIDS Research within the Mission of the NIDCD (R01 Clinical Trial Optional)
ID: 346137Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/346137

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-099.html
Timeline
    Description

    The National Institutes of Health (NIH), through the National Institute on Deafness and Other Communication Disorders (NIDCD), has announced a funding opportunity aimed at advancing HIV/AIDS research within its mission areas. This initiative encourages applications that focus on high-priority research related to communication disorders influenced by HIV/AIDS, specifically in areas such as hearing, balance, taste, smell, voice, speech, and language. The program is designed to support hypothesis-driven research, including low-risk clinical trials, with a maximum budget of $499,999 in direct costs per year and a project duration of up to five years. Interested applicants can find more details and submit their proposals by the closing date of January 7, 2026, and may contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-099-Full-Announcement.html
    PAR-23-099.html
    The National Institutes of Health (NIH), specifically the National Institute on Deafness and Other Communication Disorders (NIDCD), has announced a funding opportunity to stimulate research on HIV/AIDS within its mission areas. This opportunity encourages applications targeting high-priority research areas related to communication disorders influenced by HIV/AIDS, including hearing, balance, taste, smell, voice, speech, and language. The program supports hypothesis-driven research, with applications for low-risk clinical trials being accepted. Key dates include an open submission date of April 7, 2023, with subsequent deadlines in 2023 and 2024. Applications can be submitted by various organizations, including higher education institutions, government entities, and foreign institutions. The maximum budget allowed is $499,999 in direct costs annually, and the project period can extend up to five years. The announcement emphasizes the significance of addressing communication disorders' impact on the lives of individuals living with HIV, which affects both physical health and broader social aspects. As part of the review process, applications will be evaluated based on scientific merit, investigator qualifications, innovation, approach, and the environment where research will occur. The goal is to foster collaborations across disciplines to advance the understanding and treatment of communication challenges in people living with HIV.
    Similar Opportunities
    Advancing HIV/AIDS Research within the Mission of the NIDCD (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD (R01 Clinical Trial Optional)" aimed at stimulating research related to communication disorders associated with HIV/AIDS. This initiative encourages innovative, hypothesis-driven research that addresses high-priority areas such as hearing, speech, and language, with a focus on low-risk clinical trials that do not require FDA oversight. Eligible applicants include a wide range of organizations, such as higher education institutions and community-based organizations, with funding available up to $499,999 per year for projects lasting up to five years. Interested parties should submit their applications by January 7, 2026, and can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the announcement page at https://grants.nih.gov/grants/guide/pa-files/PAR-23-099.html.
    Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)" to stimulate research aligned with the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This initiative aims to support research on HIV-related comorbidities, gastrointestinal diseases, and metabolic disorders associated with HIV, encouraging applications from a diverse range of organizations, including higher education institutions and non-profits. With an estimated funding of $2 million for fiscal year 2025, the NIH plans to support 3 to 5 selected projects over a maximum project period of five years, with applications undergoing a rigorous peer review process. Interested applicants can find more information and submit their proposals through Grants.gov, with a submission deadline of January 7, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    NIDCD Low Risk Clinical Trials in Communication Disorders (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Deafness and Other Communication Disorders (NIDCD), has announced a funding opportunity for low-risk clinical trials in communication disorders under Funding Opportunity Number PAR-24-051. This initiative aims to support investigator-initiated projects that develop effective interventions in areas such as hearing, speech, and language, specifically targeting low-risk clinical trials that do not require FDA oversight and adhere to budget limits of under $500,000 in direct costs per year. The funding is particularly significant for enhancing research in communication disorders, ultimately improving public health outcomes through scientifically validated interventions. Interested applicants can submit proposals starting January 5, 2024, with the opportunity closing on January 8, 2028; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    NIDCD Research Opportunities for New Investigators to Promote Workforce Development (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the National Institute on Deafness and Other Communication Disorders (NIDCD) to support R01 grant applications aimed at promoting workforce development among Early Stage and New Investigators in the field of communication disorders. This initiative encourages applications from individuals from diverse backgrounds, particularly those underrepresented in health-related sciences, and allows for innovative research projects without the necessity of preliminary data, provided they demonstrate feasibility. Applicants can request up to $500,000 in direct costs per year, with a total funding commitment of approximately $2.1 million planned for fiscal years 2026 and 2027 to support around 7-8 meritorious projects. Key application dates begin on January 6, 2025, with a closing date of October 6, 2026; for further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDCD Research Grants for Translating Basic Research into Clinical Practice (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Deafness and Other Communication Disorders (NIDCD), is offering research grants aimed at translating basic research findings into clinical practice, specifically for communication disorders. This funding opportunity encourages collaborations between basic scientists and clinicians to develop practical applications that address hearing, balance, smell, taste, voice, and language disorders, with a focus on milestone-driven proposals that demonstrate a clear connection to clinical conditions and impactful outcomes. The grants, limited to a maximum of $500,000 in direct costs annually, are expected to support 2-3 awards in FY25, with applications due by October 12, 2027. Interested applicants can find more information and submit their proposals through Grants.gov, and may contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 - Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Deafness and Other Communication Disorders (NIDCD), is offering a funding opportunity titled "NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 - Clinical Trial Required)." This initiative aims to support cooperative agreements for clinical trials that require FDA oversight, are intended to establish efficacy, or present higher risks to participants, with a budget exceeding $700,000. The funding is crucial for advancing clinical practices in treating communication disorders, emphasizing the inclusion of diverse populations in recruitment and retention strategies. Interested applicants, including various educational and nonprofit organizations, must submit their applications by January 27, 2024, and can find more information at NIH Grants.
    HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research initiatives focused on HIV-associated non-communicable diseases (NCDs) at low- and middle-income country (LMIC) institutions through the R21 Clinical Trial Optional grant. This program aims to support locally relevant research that explores the relationship between HIV infection and the development of NCDs, enhance research capacity, and foster collaborative networks among researchers in LMICs and the U.S. The grant provides funding up to $275,000 over a two-year period, with a submission deadline of December 8, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for multidisciplinary research on HIV/AIDS and aging through the R21 Exploratory/Developmental Research Grant program. This initiative invites applications that aim to enhance the understanding of the biological, clinical, and socio-behavioral aspects of aging in the context of HIV infection, with specific objectives to improve prevention, testing, treatment strategies, and management of HIV-related health issues in diverse populations, particularly older adults aged 70 and above. The grant provides funding of up to $275,000 for a two-year period, with key submission dates starting April 4, 2024, and a closing date for applications set for January 7, 2027. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
    Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)." This initiative aims to encourage research into the role of inflammasomes in the neuropathology associated with HIV infection and substance use disorders, particularly focusing on their impact on neurocognitive disorders and immune function. The program seeks to bridge knowledge gaps in treatment and research by exploring how inflammasome activation is influenced by HIV and substance use, with the goal of translating findings into clinical applications. A total funding amount of $2 million is available to support up to four grants, with a submission deadline of February 13, 2024. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.